Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
Status:
Completed
Trial end date:
2020-01-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of rapamycin (sirolimus) versus a
placebo, an inactive substance, on responses to alcohol cues in individuals with alcohol use
disorder. Rapamycin (sirolimus) is a FDA-approved antibiotic and immunosuppressive drug that
is currently used to (a) prevent organ transplant recipients from rejecting their transplants
(b) treat cardiovascular diseases, and (c) treat some forms of cancer. Rapamycin (sirolimus)
is not FDA-approved to treat alcohol use disorder. The use of rapamycin (sirolimus) in this
study is investigational, meaning that the study medication is not a proven treatment for
alcohol use disorder. The study will examine the medication's use as a potential treatment
for alcohol use disorder, as well as how safe and tolerable it is to take.